REMARKS

Claims 16–77 are now pending in the present application. Claims 16, 25–28, and 34–36 are amended from those of record in Amendment A of the present application. Claims 37–77 are new according to this amendment. Each of these claims finds support in the application as filed, as indicated below.

Opportunity has been taken when preparing the present amendment to correct obvious typographical errors and to add further clarity to the claims by rewording or repunctuating where appropriate.

Claim 16 is amended to specify a "therapeutic" combination. The specification as a whole provides support for a "therapeutic" combination. It is clear from the specification as filed that the utility of the combination is for treating a disease (*i.e.*, therapeutic).

Claims 16, 35 and 36 are amended to enhance clarity by defining the one or more additional active ingredients in language that more explicitly embraces not only a single additional active ingredient but also combinations of two or more additional active ingredients. Support is found in the specification as filed, at least at paragraph **[0052]**, where it is stated that "other active ingredients . . . may also be present".

Claim 25 is amended to delete without prejudice the phrase "or an organic depression not associated with Parkinson's disease". The embodiment deleted from this claim remains the subject of Claim 27.

Claims 26–28 are amended as to dependency and to more clearly specify the antecedent class of depression recited therein.

Claim 34 is amended to specify "about" 50 mg per day as the upper end of the recited dose range. Support is found in the specification as filed, at least at paragraph **[0047]**, which indicates "approximately 50 mg/day."

Claim 35 is amended to delete without prejudice selected additional active ingredients. Combinations comprising these additional active ingredients are the subject of new Claims 68–75.

New Claim 37 recites at least 90 mol % of the compound being in the form of the S enantiomer. Support is found in the specification as filed, at least at paragraphs **[0013]** and

[0039].

New Claims 38–50 recite types of depression arranged in a hierarchy as set forth in the specification as filed, at least at paragraphs **[0027]**, **[0028]**, **[0034]** and **[0037]**.

New Claims 51–55 recite for the compound having the formula in claim 17, or racemate or enantiomer thereof or salt thereof, dose ranges of 0.1 to about 50 mg per day; 0.2 to 40 mg per day; 0.4 to 20 mg per day; 0.5 to 10 mg per day; and 0.5 to 5 mg per day respectively. Support is found in the specification as filed, at least at paragraph **[0047]**.

New Claims 56–65 recite administering additional active ingredients. Support is found in the specification as filed, at least at paragraphs **[0054]**, **[0055]** and **[0059]–[0062]**.

New Claim 66 recites that the compound having the formula in Claim 17, or racemate or enantiomer thereof or salt thereof, and the at least one additional active ingredient are provided in separate dosage forms for administration by the same or different routes at the same or different times. Support is found in the specification as filed, at least at paragraphs **[0057]** and **[0058]**.

New Claim 67 recites that the compound having the formula in Claim 17, or racemate or enantiomer thereof or salt thereof, and the at least one additional active ingredient are administered in a single dosage form. Support is found in the specification as filed, at least at paragraph **[0057]**.

New Claims 68–75 recite combinations of Claim 16, wherein the one or more additional ingredients are specified. Support is found in the specification as filed, at least at paragraphs **[0056]** and **[0059]–[0062]**.

New Claim 76 recites that the compound having the formula in Claim 16, or racemate or enantiomer thereof or salt thereof, and the one or more additional active ingredients are present in separate dosage forms adapted for administration by the same or different routes at the same or different times. Support is found in the specification as filed, at least at paragraphs **[0057]** and **[0058]**.

New Claim 77 recites that the compound having the formula in Claim 16, or racemate or enantiomer thereof or salt thereof, and the one or more additional active ingredients are present in a single dosage form. Support is found in the specification as filed, at least at

paragraph **[0057]**.

No new matter is added, and no changes in inventorship are believed to result from the present amendment.

Examination of the present application is requested following entry of this amendment. If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number below.

Respectfully submitted,

HARNESS, DICKEY & PIERCE, P.L.C.



James C. Forbes
Agent for Applicant
Reg. No. 39,457
Tel. 847-412-6350